II Congreso Nacional sobre Muerte Súbita

Expertos internacionales en cardiología, especialistas en medicina deportiva, profesionales del deporte de élite y pacientes y familiares volverán a unir sus voces y experiencias el próximo 6 de octubre en Madrid en el II Congreso Nacional de la Asociación Española contra la Muerte Súbita (AEMS), una jornada dedicada íntegramente a ofrecer una visión multidisciplinar y…

Cancer Patients Struggle with Key Aspects of Clinical Trial

Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at three to five percent. A nationwide study in Ireland (1), the preliminary results of which are to be presented at the ESMO 2017 Congress in Madrid, shows that although most…

Engineered Therapy for Blood Clotting Disorder Shows Early Promise

An investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura (TTP), according to a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Congenital TTP is characterized by blood clots…

Patients Feel Psycho-social Impact of Chemo More Acutely Than Physical Side Effects

The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid  show that socio-psychological factors have become more significant for patients today than physical side effects such as nausea and vomiting, which were among the top concerns in similar studies carried out previously.The side effects of chemotherapy seriously impact cancer…

Una molécula para el potencial tratamiento del ictus

En España las enfermedades cerebrovasculares son la segunda causa de muerte, la primera en mujeres, la primera causa de discapacidad permanente y la segunda de demencia. Hay unos 120 nuevos casos por cada 100.000 habitantes al año, y más de la mitad de los pacientes acaban incapacitados o fallecen. A pesar de su gran impacto…

El Código Sepsis, vital para la supervivencia

La SEPSIS es una dolencia crítica que se produce cuando el cuerpo, como respuesta a una infección, genera una respuesta inflamatoria que, en los casos más graves, provoca un fallo agudo de otros órganos que no necesariamente estaban relacionados con la infección original, provocando un shock o fallo multiorgánico que, en un número importante de…

Abdominal Fat a Key Cancer Driver for Postmenopausal Women

Body fat distribution in the trunk is more important than body weight when it comes to cancer risk in postmenopausal women, according to a study presented at the ESMO 2017 Congress in Madrid. (1) The findings put a new spin on weight management priorities for women in this this age-group, who are prone to abdominal…

New Tool to Assess Cancer Patients’ Palliative Needs

A new tool to identify patients who would benefit from early palliative care will be presented at the ESMO 2017 Congress in Madrid. (1)The so-called “Triggers” tool, developed by the London Cancer Alliance to help clinicians in the UK recognise patients who need an early referral to specialist palliative care, has been successfully piloted at…

Reflux Disease may be treated with diet

Among patients with laryngopharyngeal reflux, there was no significant difference in the reduction of reflux symptoms between patients treated with alkaline water and a plant-based, Mediterranean-style diet and those treated with proton pump inhibitors, according to a study published by JAMA Otolaryngology-Head & Neck Surgery. Laryngopharyngeal reflux (LPR) is a common disorder that is the…

Cuatro años de control con 20 días de tratamiento

Los resultados del ensayo clínico CLARITY Extension han sido publicados recientemente en el Multiple Sclerosis Journal. Este ensayo, que es una extensión del estudio de Fase III CLARITY, demostró que los pacientes con esclerosis múltiple remitente recurrente (EMRR) en tratamiento con Mavenclad (cladribina comprimidos) durante dos años, seguido de otros dos años con placebo, tuvieron beneficios…